Clinical Trial Update: DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating DS-3201b in combination with irinotecan for recurrent small cell lung cancer has been terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• DS-3201b
• Irinotecan (Irinotecan)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Small Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-10-10